<DOC>
	<DOCNO>NCT03052751</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy UCB7665 chronic-intermittent treatment subject generalize myasthenia gravis ( MG ) classify moderate severe .</brief_summary>
	<brief_title>Study Test Safety , Tolerability Efficacy UCB7665 Subjects With Moderate Severe Myasthenia Gravis .</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>Subject welldocumented diagnosis myasthenia gravis ( MG ) Visit 1 ( Screening ) , base subject history support previous evaluation Subject would currently consider treatment immunological therapy intravenous immunoglobulin/plasma exchange ( IVIG/PLEX ) investigator Subject document evidence his/her medical history Screening detectable autoantibody ( antiacetylcholine receptor+ve ( AntiAChR+ve ) antimuscle specific kinase+ve ( AntiMuSK+ve ) Female subject must either : postmenopausal , permanently sterilize childbearing potential applicable use highly effective method birth control Male subject must willing use method contraception Subject previously receive treatment study subject previously expose UCB7665 Subject participate another study investigational medicinal product ( IMP ; medical device ) within previous 30 day Screening currently participate another study investigational medicinal product ( IMP ; medical device ) Subject know hypersensitivity component IMP Subject history hyperprolinemia , since Lproline constituent UCB7665 IMP Subjects MG affect ocular muscle Subjects severe weakness affect oropharyngeal respiratory muscle , myasthenic crisis Screening impend crisis Subject quantitative myasthenia gravis ( QMG ) score &lt; 11 Baseline Subject serum total immunoglobulin G ( IgG ) level &lt; = 6g/L Screening Absolute neutrophil count &lt; 1500 cells/mm^3 Subject medical condition ( acute chronic illness ) psychiatric condition , opinion investigator , could jeopardize would compromise subject 's ability participate study Subject laboratory abnormality , opinion investigator , clinically significant , resolved randomization , could jeopardize would compromise subject 's ability participate study Subject receive live vaccination within 8 week prior Baseline Visit ; intend live vaccination course study within 7 week follow final dose IMP Subject receive experimental biological agent within outside clinical study past 3 month within 5 halflives prior Baseline ( whichever longer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>UCB7665</keyword>
	<keyword>Myasthenia Gravis</keyword>
</DOC>